Vertex Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir

Looks like Vertex is going to be a juggernaut in the treatment of Hepc.

- Vertex to acquire privately-held ViroChem Pharma in cash and stock transaction -- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have demonstrated significant antiviral activity in early clinical trials -- First STAT-C combination trial with telaprevir planned for 2H 2009 start -

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=368695

jasper